Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Bayer launches US$59m expansion in Beijing
Published on: 2020-08-27
Share to
User Rating: / 0
PoorBest 

bayer 02Bayer began construction of a US$59 million production and supply plant on Wednesday to expand its existing site in Beijing to enhance a stable supply of prescription drugs.

New production lines are expected to become operational by the end of 2022 and are set to increase the annual output of the Beijing site by about 40 percent.

Managing chronic disease is a key segment of the "Healthy China 2030" blueprint, and a detailed action plan was released by the State Council last July.

Ensuring a continuous supply of commonly used drugs for chronic diseases at an accessible price has been the focus of China's drug administration body and major drug companies.

bayerBayer has launched a 50-million-euro (US$59 million) expansion project for its production and supply facilities in Beijing.

Bayer Pharmaceuticals established its first plant in the Beijing Economic-Technological Development Area in 1995 and has been producing a wide range of treatments for diabetes, hypertension and other cardiovascular diseases.

In 2016, it became the largest pharmaceuticals packaging site in Bayer Pharmaceuticals Division’s global production network.

The expansion project covers production space and auxiliary technical area, which will be equipped with automated production lines and a logistics facility.

拜耳加码在华投资

拜耳启动处方药北京工厂产能提升项目,以满足中国市场未来对拜耳药品的进一步需求。该项目投资金额超过5000万欧元(折合人民币超过4亿元)。此次产能提升项目包含生产区以及配套技术区,将配备新的全自动高速生产线及配套的全自动物流系统,旨在建设成为世界级的制造工厂。新建的生产线预计于2022年底投入使用。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.